Antibody affinity and avidity are both measures of antibody-antigen binding strength, but they describe fundamentally different things. Confusing the two leads to poor antibody selection and misinterpretation of binding assay data. This guide explains the difference in clear, practical terms.
Affinity: The Strength of a Single Binding Site
Affinity (KD, dissociation constant) measures the binding strength between a single antibody binding site (paratope) and a single epitope on the antigen. It is an intrinsic property of the antibody-antigen interaction, independent of antibody format or valency.
KD is typically measured in molar units (M). A lower KD means stronger binding:
| KD Range |
Binding Strength |
Typical Application |
| 10−6–10−7 M (µM) |
Low affinity |
Polyclonal serum; early-stage clones |
| 10−8–10−9 M (nM) |
Moderate to high affinity |
Standard monoclonal antibodies |
| 10−10–10−12 M (sub-nM) |
Very high affinity |
Affinity-matured therapeutic antibodies |
Affinity is typically measured by surface plasmon resonance (SPR, e.g., Biacore) or bio-layer interferometry (BLI, e.g., Octet), which provide both the association rate (kon) and dissociation rate (koff). KD = koff / kon.
Avidity: The Combined Strength of All Binding Sites
Avidity describes the overall strength of the antibody-antigen interaction when multiple binding sites engage simultaneously. An IgG antibody has two binding sites (bivalent); an IgM has ten (pentavalent). When both arms of an IgG bind the same multivalent antigen (e.g., two copies of the same epitope on a cell surface), the effective binding strength is much greater than a single arm’s affinity alone.
Think of it this way: affinity is the strength of one hand gripping a bar. Avidity is the strength of both hands gripping the bar simultaneously—even if each hand is individually weak, the combined hold is much stronger because both would need to let go at the same time.
The Practical Impact
An IgM with moderate single-site affinity (K₄ ~10⁻⁶ M) can have an apparent avidity equivalent to an IgG with K₄ ~10⁻¹⁰ M, simply because its ten binding sites create a near-irreversible interaction when engaging a multivalent antigen.
Why the Difference Matters for Antibody Selection
| Scenario |
What Matters More |
Why |
| ELISA (antigen coated on plate) |
Avidity |
Multiple copies of antigen on the plate surface allow bivalent binding—high avidity compensates for moderate affinity |
| Flow cytometry (cell surface antigens) |
Avidity |
Clustered epitopes on cell surface favor multivalent binding |
| Western blot (denatured, linear epitope) |
Affinity |
Single epitope presented linearly; bivalent binding unlikely |
| SPR/BLI kinetic measurement |
Affinity |
Instruments measure single-site K₄ under controlled conditions |
| In vivo therapeutic use |
Both |
High affinity for specificity; avidity for tumor cell retention and Fc-mediated effector functions |
Common Misconceptions
- "Higher affinity is always better." Not necessarily. For flow cytometry staining, an antibody with moderate affinity but high avidity (due to bivalent binding to clustered surface epitopes) often performs better than a monovalent high-affinity fragment.
- "Polyclonal antibodies have higher affinity." Polyclonal antibodies are a mixture—individual clones within the pool have varying affinities. The apparent high performance often reflects high avidity from multi-epitope binding, not individual clone affinity.
- "KD tells you everything about antibody performance." KD is measured under controlled conditions with purified components. In a complex assay like IHC, factors like tissue penetration, fixation-induced epitope changes, and blocking agent interference also determine performance.
Key Takeaways
- Affinity = one binding site + one epitope. Intrinsic to the antibody-antigen pair.
- Avidity = all binding sites + all epitopes. Depends on antibody format and antigen presentation.
- For most research applications, avidity-driven performance (ELISA, flow cytometry, IHC) matters more than raw affinity.
- When comparing antibodies, check both KD data (if available) and application-specific validation data.
Explore High-Affinity Antibodies →
中文
English
한국어
日本語
Español
Français
Русский
